Previous Article | Next Article ![]()
Infection and Immunity, August 1999, p. 3740-3749, Vol. 67, No. 8
Department of Medicine, Division of
Infectious Diseases, University of Washington, Seattle, Washington
Received 19 January 1999/Returned for modification 2 April
1999/Accepted 10 May 1999
Haemophilus ducreyi, the causative agent of chancroid,
produces a hemolysin, whose role in virulence is not well defined. To
assess the possible role of hemolysin in pathogenesis, we evaluated its
target cell range by using wild-type H. ducreyi 35000, nonhemolytic mutants with the hemolysin structural gene deleted, and
isogenic strains expressing different amounts of hemolytic activity.
The cytotoxicity of the various cell types was assessed by quantitating the release of lactate dehydrogenase into culture supernatants as a
measure of cell lysis. In these experiments, human foreskin fibroblasts, human foreskin epithelial cells, and, to a lesser extent,
HEp-2 cells were lysed by H. ducreyi hemolysin. Hemolysin also lysed human blood mononuclear cells and immune system cell lines
including U937 macrophage-like cells, T lymphocytes, and B lymphocytes.
In contrast, human polymorphonuclear leukocytes were not sensitive to
hemolysin under the conditions tested. We also analyzed the effect of
hemolysin on invasion of human epithelial cells and found that H. ducreyi strains expressing cloned hemolysin genes showed a
10-fold increase in invasion compared to the control strain. These data
support the hypothesis that the H. ducreyi hemolysin is
important in the pathogenesis of chancroid and may contribute to ulcer
formation, invasion of epithelial cells, and evasion of the immune response.
Haemophilus ducreyi is a
gram-negative bacterium that causes the sexually transmitted genital
ulcer disease chancroid. Chancroid ulcers are painful and can persist
for several months if untreated, exposing the patient to secondary
infections (20). Inguinal lymphoadenopathy occurs in up to
50% of chancroid patients (20), and chancroid ulcers have
been associated with increased heterosexual transmission of human
immunodeficiency virus (6, 25, 45). Chancroid is most common
in developing countries, although outbreaks occur in the United States,
especially among individuals of lower socioeconomic status
(43). Diagnosis of chancroid can be difficult since ulcers
often resemble those of syphilis or herpes and isolation of H. ducreyi from lesions is frequently unsuccessful (43). For these reasons, the incidence of chancroid is probably higher than
is currently recognized.
The initiation and progression of chancroid lesions has been studied by
using human and animal models of chancroid (28, 34, 35, 40,
43). Three to ten days after inoculation with H. ducreyi, a papule develops, which either resolves or progresses to
form a pustule. The pustule eventually ulcerates and involves cells of
both the epidermis and the dermis (20). Histopathological analysis demonstrates that typical chancroid lesions consist of a deep
necrotic ulcer containing disintegrating epithelial cells (20) and an infiltrate of polymorphonuclear leukocytes
(PMNs), Langerhans' cells, macrophages, and CD4+ T cells (34,
35). Despite the presence of these inflammatory cells, the
lesions persist if untreated and viable H. ducreyi can be
recovered. Several potential virulence factors, including
lipooligosaccharide (7), cytolethal distending toxin
(9, 29), fine tangled pili (5), and a
cell-associated hemolysin (22, 41), have been identified, although their contribution to the pathogenesis of chancroid is not
well understood.
Expression of the cell-associated hemolysin of H. ducreyi
requires two adjacent genes, hhdB and hhdA
(23), which are similar to the hemolysins of Serratia
marcescens, Edwardsiella tarda, and Proteus
mirabilis (23, 27, 44). The S. marcescens
hemolysin, encoded by shlB and shlA, is the most
thoroughly characterized of this group of hemolysins. ShlB is an outer
membrane protein, which is required for secretion and activation of the
hemolysin structural protein, ShlA (4, 32). Once secreted,
ShlA interacts with target cell membranes, oligomerizes, and forms
pores 2.5 to 3.0 nm in diameter, which lyse the target cell
(33).
The effect of the H. ducreyi hemolysin on some human cell
types has been previously examined (2, 21). These studies
demonstrated the cytotoxic effect of the H. ducreyi
hemolysin on human foreskin fibroblasts (HFFs) by using H. ducreyi 35000 and isogenic transposon mutants with insertions in
hhdB (2, 11, 21). In the present study, we
examined the range of cell types with which the hemolysin can interact
by using a mutant with a deletion in hhdA and cloned hemolysin genes expressing different amounts of hemolysin. We found
that in addition to its action on erythrocytes (RBCs) and HFFs, the
hemolysin can lyse other cell types relevant to chancroid including
human foreskin epithelial cells (HFEs) and immune system cells such as
macrophages, T cells and B cells. In addition, we found that hemolysin
enhances the invasion of HEp-2 epithelial cells. These results
are consistent with a role for hemolysin in tissue destruction and/or
immune system avoidance in chancroid ulcers.
Bacterial strains and plasmids.
The bacterial strains and
plasmids used in this study are described in Table
1 and Fig.
1. Human cell lines were obtained from
the American Type Culture Collection (Manassas, Va.).
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Target Cell Range of Haemophilus ducreyi
Hemolysin and Its Involvement in Invasion of Human Epithelial
Cells
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Bacterial strains and plasmids used in this study

View larger version (17K):
[in a new window]
FIG. 1.
Plasmids used in this study and their hemolytic
activities in 35000
APC. *, data is expressed as a percentage of
the hemolytic activity of strain 35000; the mean of a typical
experiment performed in duplicate is shown with standard error. The
experiment was repeated at least three times with similar results. The
hemolytic activities of 35000
APC and 35000
APC(pLSSK) were 0.13% ± 0.00% and 0.66% ± 0.52%, respectively. B, BglII; D,
DraIII; F, FspI; H, HindIII; Hp,
HpaI; N, NcoI; P, PstI.
Media and growth conditions.
H. ducreyi strains were
maintained as frozen suspensions in 50% glycerol at
70°C and
cultured on chocolate agar with enrichment (PML Microbiologicals,
Wilsonville, Oreg.) at 35°C in candle jars for 48 h. Liquid
cultures were grown aerobically in Hd broth (42) at 35°C
with shaking for 16 to 20 h. Mid-logarithmic-phase cultures were
prepared by diluting overnight cultures 1:5 in fresh Hd broth and
incubating them for 4 to 5 h with shaking at 35°C. Antibiotic concentrations for H. ducreyi were 50 µg of streptomycin
per ml, 1 to 2 µg of chloramphenicol per ml, and 10 µg of
ampicillin per ml. Escherichia coli and Salmonella
typhimurium cultures were grown in Luria-Bertani (LB) broth or on
LB agar plates (31) supplemented, when appropriate, with 100 µg of streptomycin per ml, 30 µg of chloramphenicol per ml, or 100 µg of ampicillin per ml.
Manipulation of DNA. Standard techniques were used for the isolation and manipulation of plasmid and chromosomal DNA (31). Restriction enzymes, T4 DNA ligase, T4 DNA polymerase, and oligonucleotide primers were purchased from Gibco BRL Life Technologies (Gaithersburg, Md.); deoxynucleoside triphosphates (dNTPs) were purchased from Promega (Madison, Wis.).
Construction of an isogenic, hemolysin-deficient H. ducreyi mutant.
Strain 35000
APC, a hemolysin-deficient
mutant of strain 35000, was constructed as follows. First, the 5.2-kb
SstI-SalI insert of pPT376 (41)
containing part of hhdB and all of hhdA was
cloned into pBluescript KS(
) (Stratagene). The resulting plasmid,
pPT376KS, was digested with PstI to delete a 2.6-kb internal
fragment of hhdA, treated with T4 DNA polymerase to produce
blunt ends, and then ligated to BamHI linkers (Promega),
creating pPT376
Pst. The 1.2-kb BamHI fragment of
pUC-
Ecat containing the chloramphenicol acetyltransferase
(cat) gene was then cloned into the BamHI site of
pPT376
Pst to produce pPT376
PstCm. Thus, the
hhdA::cat construct on pPT376
PstCm
expresses only the first 182 amino acids of HhdA. Plasmid
pPT376
PstCm was introduced into wild-type H. ducreyi 35000 by electroporation, and transformants were selected on charcoal agar plates containing 1 µg of chloramphenicol per ml. A total of 23 transformants were obtained, of which 10 were nonhemolytic on bilayer
horse blood agar plates (41). Of the 10 nonhemolytic transformants, 7 were subjected to analysis by PCR with primers A start
and rev A end (Table 2) under the
following conditions: 2 min at 92°C, followed by 30 cycles of 45 s at 92°C, 1 min at 63°C, and 5 min at 68°C, and ending with 7 min at 68°C, in a reaction mixture containing 50 mM Tris (pH 9.2), 16 mM (NH4)2SO4, 5 mM MgCl2, 0.5 mM total dNTPs, 0.3 µM (each) primer, and 2.5 U of Long Extend Polymerase (Boehringer Mannheim, Indianapolis, Ind.). A 3.6-kb PCR product was amplified from wild-type hhdA,
while a product of 2.2 kb was obtained for the
hhdA::cat allele. PCR products of 3.6 and 2.2 kb were amplified from six of the seven clones tested,
indicating that they resulted from single crossovers and contained both
wild-type hhdA and
hhdA::cat; these were discarded. A
single product of 2.2 kb was amplified from the seventh clone, indicating replacement of wild-type hhdA with the
hhdA::cat allele. This clone was named
35000
APC and was subjected to Southern blot analysis, which
confirmed deletion of the wild-type hhdA allele (data not
shown). 35000
APC is nonhemolytic both on bilayer horse blood agar
plates and in liquid hemolysin assays and can be complemented with
hhdA (data not shown).
|
Construction of pLSSK and pLSKS.
Plasmids pLSSK and pLSKS,
derivatives of pLS88 (48), were constructed as described
below and in Fig. 2. First, a 3-kb PCR product was amplified from pLS88 with primers 88R and 88BFD (Table 2)
under the following conditions: 3 min at 94°C, followed by 30 cycles
of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C, and ending
with 10 min at 72°C, in a reaction mixture containing 2.5 mM
MgCl2, 10 mM Tris (pH 8.3), 50 mM KCl, 0.5 mM (total)
dNTPs, 0.36 µM (each) primer, and 0.5 U of Taq polymerase
(Sigma, St. Louis, Mo.). The PCR product was digested with
BglII and self-ligated to form plasmid pBFD. pBFD thus
contains the origin of replication and genes for streptomycin and
sulfonamide resistance. Next, the lacZ
gene and the
multiple-cloning site of pBluescript SK(
) (Stratagene) were PCR
amplified with primers 5'BlueMCS and 3'BlueMCS (Table 2) under the
conditions described above, except that 5 mM MgCl2 and 0.10 µM primers were used. This 441-bp PCR product was cloned into pCR2.1
with the TA cloning kit as specified by the manufacturer (Invitrogen).
The resulting plasmid was digested with BclI and ligated
into the BglII site of pBFD, generating pLSSK. Plasmid pLSKS
was constructed similarly, except that the lacZ
gene and
multiple-cloning site was amplified from pBluescript KS(
). Therefore,
pLSKS is identical to pLSSK, except that the multiple-cloning site is
reversed. Both pLSSK and pLSKS are similar to pLS88 in that they encode
streptomycin and sulfonamide resistance and replicate in both E. coli and H. ducreyi; however, they have the additional
advantages that they are smaller, contain a multiple-cloning site, and
allow blue-white color selection in E. coli.
|
Construction of hemolysin-encoding plasmids. The plasmids used in this study are shown in Table 1 and Fig. 1, and their construction is described below. Plasmid pLSBA+2 was derived from pBABN, whose construction is described elsewhere (11). Briefly, pBABN carries hhdBA, wherein hhdB has been altered so that it has the E. coli consensus ribosome binding site and hhdA lacks the native stop codon. The entire 5.2-kb fragment was cloned into the BamHI-SalI sites of pLSSK so that transcription proceeds from the vector-encoded lac promoter. The resulting plasmid was named pLSBA+. To restore the native stop codon to hhdA on pLSBA+, a 334-bp PCR product was amplified from H. ducreyi 35000 chromosomal DNA with primers NcoF and A end Sal (Table 2) under the following conditions: 2 min at 94°C, followed by 30 cycles of 1 min at 94°C, 1 min at 55°C, and 2 min at 72°C, and ending with 7 min at 72°C, in a reaction mixture containing 50 mM Tris (pH 9.2), 16 mM (NH4)2SO4, 5 mM MgCl2, 0.5 mM (total) dNTPs, 0.3 µM (each) primer, and 2.5 U of Taq DNA polymerase (Promega). This 334-bp product was sequenced to confirm that no mutations had been introduced during amplification (data not shown), digested with HpaI and SalI, and used to replace the corresponding fragment of pLSBA+ (the HpaI site is within the PCR fragment). The resulting plasmid, named pLSBA+2 (Fig. 1), contains hhdBA and 167 bp of DNA downstream of the hhdA stop codon. Since pLSBA+2 lacks sequence upstream of hhdBA, expression proceeds from the vector-encoded lac promoter.
Plasmid pLSB+ (Fig. 1) was derived from pLSBAHis (11). Plasmid pLSBAHis was digested with HindIII and then religated to form pLSB+. Thus, pLSB+ contains hhdB expressed from the vector-encoded lac promoter and an E. coli consensus ribosome binding site, and the first 290 bp of hhdA on pLSSK. pLS384-2 (Fig. 1) is identical to pLSBA+2, except that it contains the region 5' to hhdB, which is believed to contain the hhdB promoter and has the native ribosome binding site (23). pLS384-2 was constructed from pLS384
(not shown),
which contains the 7.0-kb SmaI-SalI fragment of
pPT384-TZ18 (41) in pLSKS. pLS384
thus carries ~1.0 kb
of DNA downstream of hhdA. To delete this downstream DNA,
the 3' HpaI-SalI fragment of pLS384
was replaced with a smaller, PCR-amplified fragment containing only 167 bp
of DNA downstream of hhdA in the same manner as described above for pLSBA+2. The resulting plasmid was named pLS384-2.
pLS376
was constructed by cloning the 5.8-kb
SalI-SmaI fragment of pPT376 (41) into
pLSKS. pLS376
thus contains the C-terminal 470 bp of hhdB
and the full-length hhdA genes transcribed opposite the
vector-encoded lac promoter.
Liquid hemolysin assays. Quantitative hemolysin assays were performed on logarithmic-phase cultures (1.5 ml), which were microcentrifuged for 1 min and then resuspended in 1 ml of 0.85% NaCl-10 mM CaCl2. Serial twofold dilutions were made in 96-well round-bottom plates in the same buffer, and washed horse RBCs (ca. 1% [wt/vol]) were added to each well. After a 1-h incubation at 37°C, the plate was centrifuged for 10 min at 500 × g, 100 µl of the supernatant was removed, and the absorbance at 540 nm was determined. All hemolytic values are the average of duplicate samples and represent the dilution of the test culture (at OD540 = 1.0) that lyses 50% of the RBCs. This hemolytic activity was determined by using the following equation: hemolytic activity = percent lysis/(50 × OD540 × D). Percent lysis was determined by comparison to RBCs lysed with distilled water (total lysis), OD540 is the optical density of the test culture at 540 nm, and D is the dilution of the test culture. The hemolytic activity of the strains varied from experiment to experiment (up to threefold), but the relative amounts of hemolytic activity were consistent between strains within experiments.
Cell culture. HEp-2 (ATCC CCL-23), U937 (ATCC CRL-1593), Daudi (ATCC CCL-213), Jurkat (ATCC TIB-152), and Raji (ATCC CCL-86) cells were cultured, at 37°C in a humidified atmosphere of 5% CO2 and 95% air, in RPMI 1640 medium supplemented with glutamine (ICN Biomedicals, Inc., Aurora, Ohio), sodium bicarbonate (Sigma), and 10% fetal bovine serum (Gibco BRL Life Technologies). Primary cultures of HFEs and HFFs were obtained as previously described (3) and maintained in keratinocyte serum-free medium (KSFM; Gibco BRL Life Technologies) or RPMI 1640 medium, respectively. Twice weekly, HEp-2, HFF, or HFE monolayers were treated with a solution of trypsin-EDTA (Gibco BRL Life Technologies) to produce a single-cell suspension and then plated at a dilution of 1:20 in fresh medium. U937, Daudi, Jurkat, and Raji cells were also split twice weekly by being diluted 1:20 in fresh medium. To induce adherence, U937 cells were treated for 24 h with 250 ng of phorbol myristate acetate (Sigma) per ml of culture medium. Adherent U937 cells were washed once with balanced salt solution, scraped into culture medium with a glass rod, washed once in fresh culture medium, and then used in the cytotoxicity assay as described below.
Isolation of monocytes and PMNs from human blood. Fresh venous blood (30 ml) from healthy volunteers was collected in EDTA-treated tubes and immediately processed for isolation of mononuclear cells and PMNs in using MonoPoly Resolving Medium (ICN Biomedicals, Inc.) as specified by the manufacturer. Purified cells were stained to confirm morphology by using the Diff-Quik stain set (Dade Diagnostics, Aguada, P.R.). PMN preparations consisted of >99% PMNs; mononuclear cell preparations were mixtures of monocytes, lymphocytes, and platelets. Cells were used in cytotoxicity assays immediately after isolation.
Cytotoxicity assays. Approximately 4 h before each assay, 2 × 104 (HEp-2, HFF, and HFE) or 5 × 104 (U937, Daudi, Raji, Jurkat, mononuclear cells, and PMNs) cells were plated in 96-well flat-bottom plates in RPMI 1640 medium-1% fetal bovine serum or KSFM as appropriate. Overnight cultures of H. ducreyi strains were diluted 1:5 in Hd broth (42) and incubated at 35°C for 5 h with shaking. These bacterial samples (1.5 ml) were microcentrifuged for 1 min and then resuspended in RPMI 1640 medium-1% fetal bovine serum or KSFM (1 ml); the culture densities were similar between experiments. Dilutions (1:5 to 1:500) of each bacterial sample were made, and 100 µl was added to quadruplicate wells. The plate was centrifuged for 10 min at 150 × g and then incubated at 37°C in humidified 5% CO2-95% air for 3 h. A 50-µl volume of the supernatant was tested for lactate dehydrogenase (LDH) activity by the CytoTox 96 nonradioactive cytotoxicity assay (Promega) as specified by the manufacturer. The normalized LDH activity was calculated in the same manner as the hemolytic activities described above. Complete lysis of target cells for controls was achieved by freezing and thawing (HEp-2 cells) or treatment with Triton X-100 (all other cell types). Liquid hemolysin assays were performed on test bacterial cultures at the same time as the cytotoxicity assays.
Invasion and adherence assays. HEp-2 cells were seeded into 24-well plates at a density of 5 × 105 to 1 × 106 cells per well and incubated for 16 to 20 h. Overnight cultures of H. ducreyi were diluted 1:5 in Hd broth and incubated with shaking for 4 to 5 h at 35°C. The cultures were then microcentrifuged for 1 min and resuspended in cell culture medium to an approximate OD540 of 1.0. Overnight cultures of E. coli HB101 were diluted 1:200 in LB broth and grown with shaking at 35°C. S. typhimurium SL1344 was grown overnight in LB broth at 37°C without shaking and then diluted 1:25 in LB broth and incubated for 4 to 5 h without shaking. SL1344 and HB101 were microcentrifuged for 1 min and then resuspended in culture medium to an approximate OD540 of 0.1. Each bacterial suspension was then diluted 1:10 in culture medium, and 100 µl of this dilution was added to triplicate wells of HEp-2 cells. The plate was centrifuged for 10 min at 150 × g and then incubated at 37°C in humidified 5% CO2-95% air for 1 h. The wells were washed three times with warm phosphate-buffered saline and then incubated for 1 h with 1 ml of culture medium containing 30 µg of gentamicin. Three washes with phosphate-buffered saline were performed, and then HEp-2 cells were lysed with trypsin-EDTA. Released bacteria were diluted in LB broth and plated on chocolate agar (H. ducreyi) or LB agar (HB101 and SL1344). All strains were similar in their sensitivity to gentamicin (data not shown).
Adherence of H. ducreyi strains to HEp-2 cells was measured as previously described (39), except that adherence was measured after a 90-min incubation.Statistical methods. Student's t distribution was used to determine P values for differences between sample means (37).
| |
RESULTS |
|---|
|
|
|---|
Development of the cytotoxicity assay.
The goal of this study
was to determine the target cell range of the H. ducreyi
cell-associated hemolysin. However, previous studies have suggested
that the target cell range of the secreted cytolethal distending toxin
might overlap that of the hemolysin, making it difficult to determine
the contribution of each toxin separately (21). Since
hemolysin is poorly expressed in E. coli (11), we
developed an assay to measure cytotoxicity in H. ducreyi, which would minimize the possible effects of the cytolethal distending toxin or other unidentified toxins. In this assay, H. ducreyi cultures were grown to the mid-logarithmic phase to induce
hemolysin expression, the bacterial cells were washed to reduce the
amount of secreted cytolethal distending toxin introduced into the
assay mixture, and LDH activity was measured after only 3 h of
coincubation with target cells. Initial experiments to evaluate this
assay were performed with HFFs since previous studies have shown that the hemolysin is cytotoxic to these cells (2, 21). To
confirm these observations, we constructed a mutant of H. ducreyi 35000 by replacing hhdA with
hhdA::cat via allelic exchange (see
Materials and Methods and Fig. 1). The resulting mutant was named
35000
APC and is nonhemolytic both on bilayer horse blood agar plates
and in liquid hemolysin assays (data not shown). Cytotoxicity assays with these strains demonstrated that strain 35000 caused the release of
approximately 5% of the total cellular LDH from HFFs while 35000
APC
caused the release of only 1% of the LDH (Fig.
3), confirming previous observations that
hemolysin is a fibroblast contact cytotoxin (2, 21). While
this difference was statistically significant (P < 0.001), the low levels of LDH released suggested that this assay
may be insufficiently sensitive to detect the activity of hemolysin on
other cell types.
|
APC with the hemolysin-expressing plasmids pLSBA+2 or
pLS384-2 caused the release of large amounts of LDH (
100% compared
to lysis by Triton X-100) from HFFs, substantially more than that
released by the control consisting of vector alone
[35000
APC(pLSSK)] (Fig. 3). Thus, a short (3-h) coincubation of
H. ducreyi strains expressing cloned hemolysin genes with
HFFs was cytotoxic, similar to results obtained with wild-type
hemolysin expression and long incubation times (24 h) (2,
21). To rule out the possibility that HhdB caused the observed
cytotoxicity, we constructed a plasmid (pLSB+, Fig. 1) which carries
only hhdB. As expected, 35000
APC(pLSB+) was neither
hemolytic (Fig. 1) nor cytotoxic, causing the release of <1% of the
LDH, comparable to the control 35000
APC(pLSSK) (Fig. 3). In
contrast, pLS376
, which carries only hhdA, expressed ca.
40% of the hemolytic activity of the wild-type strain 35000 (Fig. 1)
and restored a corresponding level of cytotoxicity to 35000
APC (Fig.
3). Because the levels of hemolytic activity and cytotoxicity were very
low for this strain, 35000
APC(pLS376
) was excluded from further
cytotoxicity assays.
To determine if LDH release correlated with hemolytic activity,
dose-response experiments were performed with 35000
APC(pLSBA+2) and
35000
APC(pLS384-2) compared to the wild-type strain 35000 (Fig.
4). In these experiments, lysis of HFFs
paralleled lysis of RBCs for 35000
APC(pLSBA+2) and
35000
APC(pLS384-2) at all bacterial cell concentrations,
demonstrating a correlation between hemolytic activity and
cytotoxicity. These experiments also demonstrated that horse RBCs are
more sensitive than HFFs to lysis by hemolysin-producing H. ducreyi strains even though hemolysis was measured after only a
1-h incubation whereas LDH release was measured after a 3-h incubation.
This difference was not due to the different buffers used for the
cytotoxicity and hemolysin assays, since the hemolytic activity of the
strains was similar in both media (data not shown). Strain 35000 was
not as cytotoxic as expected from its hemolytic activity, perhaps
suggesting that (i) a threshold number of hemolysin molecules are
needed to lyse HFFs, (ii) HFFs are able to repair damage caused by the
lower levels of hemolysin, or (iii) inhibition or degradation of
hemolysin by other cellular factors can be overcome with higher levels
of hemolysin.
|
H. ducreyi hemolysin is cytotoxic for human epithelial
cells.
Our cytotoxicity assay with strains expressing cloned
hemolysin genes and short incubation times was consistent with previous results showing that wild-type levels of hemolysin are cytotoxic to
HFFs after a 24-h cocultivation (2, 21). We therefore expanded our analysis of the target cell range of hemolysin to other
epidermal cells including a human epithelial cell line (HEp-2) and
primary cultures of HFEs (Table 3). To
compare the relative cytotoxicity between experiments and cell types,
LDH release was adjusted to 50% and corrected for slight differences
in the turbidity of test cultures (normalized LDH release [see
Materials and Methods]). For comparison, the data demonstrating
cytotoxicity of hemolysin for HFFs (Fig. 3) are recalculated and
presented in Table 3 as normalized LDH release. In these experiments,
HFEs and HEp-2 cells were lysed by 35000
APC(pLSBA+2) or
35000
APC(pLS384-2) but not by 35000
APC(pLSSK), similar to the
results with HFFs. Strain 35000 did not cause significant cytotoxicity
for HFEs or HEp-2 cells in this assay with short incubation times.
Significantly, 35000
APC and 35000
APC(pLSSK) were not cytotoxic in
these assays, indicating that LDH release due to other H. ducreyi products including cytolethal distending toxin was not
significant in our assay, even though the cytolethal distending toxin
acts on HEp-2 cells during extended incubations (9, 29). As
expected, 35000
APC complemented with hhdB alone (pLSB+)
was not cytotoxic.
|
H. ducreyi hemolysin lyses human immune system
cells.
We next assessed the ability of the H. ducreyi
hemolysin to lyse human immune system cells by using both cells freshly
isolated from human blood and several immune system cell lines. Human
PMNs and mononuclear cells were separated by density gradient
centrifugation and analyzed for their susceptibility to hemolysin
(Table 4). In these experiments,
cytotoxicity attributable to hemolysin was observed in the mononuclear
cell fraction, which contained monocytes, lymphocytes, and
platelets. Both 35000
APC(pLSBA+2) and
35000
APC(pLS384-2) were cytotoxic with normalized LDH
values of 1.52 and 44.53, respectively, consistent with their relative
hemolytic activities. As expected, 35000
APC, 35000
APC(pLSB+), and
35000
APC(pLSSK) were not cytotoxic and the amount of hemolysin
produced by strain 35000 in these experiments was not sufficient to
cause cytotoxicity to mononuclear cells (Table 4). In contrast to the
results seen with mononuclear cells, the low levels of LDH released
from PMNs incubated with 35000
APC(pLSBA+2) and 35000
APC(pLS384-2)
suggested that this cell type is relatively insensitive to lysis by
hemolysin under these experimental conditions (Table 4).
|
APC(pLSBA+2) and
35000
APC(pLS384-2) but not by 35000
APC with vector alone
(pLSSK) or hhdB alone (pLSB+). The normalized LDH values for
35000
APC(pLSBA+2) and 35000
APC(pLS384-2) were 5.67 and 69.62, respectively, compared to 0.18 for 35000
APC(pLSSK) (P < 0.001). The wild-type strain 35000 was only slightly cytotoxic (0.35 ± 0.05) for this cell line. Similar results were obtained with T lymphocytes (Jurkat cells), with hemolysin-expressing clones causing significantly more LDH release than the control with vector alone. Among the B-lymphocyte lines, Daudi cells were more sensitive to
lysis by hemolysin than were Raji cells. Both cell lines released similar amounts of LDH after incubation with 35000
APC(pLSBA+2). However, Daudi cells were ca. sevenfold more sensitive to lysis by
35000
APC(pLS384-2) than Raji cells were. Both cell lines were minimally affected by the hemolysin levels produced by strain 35000.
|
APC(pLS384-2). In this analysis, we
found that T cells were the most sensitive to hemolysin-mediated lysis
(i.e., had the lowest ratio of hemolytic activity to normalized LDH)
followed by U937 macrophage-like cells, HFEs, HFFs, and Daudi cells.
Raji and HEp-2 cells were only modestly affected by hemolysin, while PMNs were not lysed by any of the strains under these conditions.
|
H. ducreyi hemolysin enhances invasion of human
epithelial cells.
Since H. ducreyi has previously been
found to invade HEp-2 cells and HFEs (39), we examined the
role of hemolysin in invasion of HEp-2 cells by the hemolysin-deficient
mutant, strains expressing cloned hemolysin genes, and strain 35000 (Fig. 5). Low multiplicities of infection
(1 to 10 CFU per epithelial cell) and short incubation times (1 h) were
used to minimize cytotoxicity to HEp-2 cells by the hemolysin. The
highly invasive S. typhimurium SL1344 (16) and
the noninvasive E. coli HB101 served as positive and
negative controls, respectively. Invasion of HEp-2 cells by 35000 ranged from 0.25 to 0.95% of the inoculum, consistent with
previous results (39). Invasion by 35000
APC was not
significantly different from invasion by 35000, 35000
APC(pLSSK), or 35000
APC(pLS376
). Similarly, invasion
by strain 35000
APC(pLSBA+2) was not significantly different from
invasion by 35000 or 35000
APC(pLSSK) (P < 0.10); however, 35000
APC(pLS384-2) invaded significantly more than
35000(pLSSK) (P = 0.05), at levels similar to those
of SL1344. Coinfection experiments showed that 35000
APC(pLS384-2)
did not enhance uptake of HB101, suggesting that increases in invasion
were specific to the bacterial cell producing hemolysin (data not
shown). Furthermore, plasmid pLSB+ did not affect invasion by
35000
APC, indicating that HhdB alone plays no direct role in the
invasion of these cells (Fig. 5).
|
APC, 35000
APC(pLSSK), and 35000
APC(pLS384-2) to
HEp-2 cells and found that all four strains adhered at similar levels
(data not shown). These results suggest that the hemolysin is not
acting as an adhesin in these experiments but instead acts at a
different step in the invasion process.
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we found that the target cell range of the H. ducreyi cell-associated hemolysin includes T cells, macrophages, HFEs, HFFs, and B cells. T cells and macrophages were the cell types most affected by hemolysin, followed by HFEs, HFFs, B cells, and HEp-2 cells, while PMNs were relatively insensitive to lysis by hemolysin in our experiments. In addition, we showed that hemolysin expression enhances the invasion of H. ducreyi into HEp-2 cells and that this invasion is specific for H. ducreyi, since hemolysin-producing strains did not allow the invasion of E. coli in coinfection experiments.
In addition to expanding the cell range of hemolysin on clinically relevant cell types, our experiments differed in several ways from previous studies showing the cytotoxicity of hemolysin for HFFs and HaCaT cells (2, 21). First, previous studies (2, 11, 21) used mutants with mutations in hhdB rather than hhdA to demonstrate differences in wild-type and hemolysin mutant activity. The hhdA gene encodes the hemolysin structural protein based on the hemolytic activity of purified HhdA (11) and the homology of hhdA to the S. marcescens shlA hemolysin gene (23, 27, 41). HhdB is probably involved in secretion and activation of HhdA, similar to its homologue, the S. marcescens shlB gene (4, 32). While HhdB activity may be specific to HhdA, it is also possible that this protein affects the secretion and/or activation of other, as yet unidentified, proteins of H. ducreyi. Second, we used quantitative LDH release assays, cloned hemolysin genes, and modified incubation conditions to analyze the effect of this cell-associated hemolysin and minimize the effect of the secreted cytolethal distending toxin (9, 29). We showed that the results of these short-term cytotoxicity assays, using strains expressing cloned hemolysin genes, mimic results obtained for HFFs with wild-type-hemolysin-expressing strains and long exposure times (2, 21). These modifications allowed us to determine the specificity of the hemolysin for many cell types important in chancroidal disease while avoiding the contaminating effects of other H. ducreyi toxins. We hypothesize that since macrophages, T cells, and HFEs were more sensitive than HFFs to overexpressed hemolysin, they are also likely targets for wild-type levels of hemolysin in the previously described cocultivation assay (2, 21). The interaction of hemolysin with B cells and HEp-2 cells needs to be studied further to determine if this level of sensitivity is relevant to wild-type hemolysin expression levels.
The target cell specificity of hemolysins (cytolysins) from other organisms is thought to partially define the host range and disease manifestation in the host. For example, the RTX leukotoxins LktA of Pasteurella haemolytica and AaltA of Actinobacillus actinomycetemcomitans lyse only ruminant or primate leukocytes, respectively, suggesting a role in attenuating the immune response to these organisms (47). However, other RTX hemolysins, including HlyA of E. coli, AppA of Actinobacillus pleuropneumoniae, and CyaA of Bordetella pertussis, have a broad target cell range including RBCs and nucleated cells from different species, suggesting a broader role in pathogenesis (47). The Proteus mirabilis hemolysin (hpmBA), which is homologous to the H. ducreyi hemolysin, has a broad cell target range which includes human bladder and renal epithelial cells, B cells, monocytes, and African green monkey kidney cells (8, 38). Similarly, the H. ducreyi hemolysin appears to have a broad target cell range, as demonstrated here and by previous work (22, 41), suggesting that the hemolysin is important in the interactions of H. ducreyi with many cell types in chancroidal lesions. For example, hemolysin may contribute to ulcer formation by lysing keratinocytes or fibroblasts. Chancroid ulcers contain large numbers of T cells and macrophages, and yet viable H. ducreyi persists in these lesions (20). Our observation that T cells and macrophages are sensitive to hemolysin may suggest a role for hemolysin in inhibition of an effective cell-mediated immune response that clears the H. ducreyi infection. While the data presented here defines the target cell range of hemolysin and the relative sensitivity of the various cell types to hemolysin, further experiments are needed before we can determine the in vivo relevance of this target cell range, including the effect of hemolysin on virulence and survival of H. ducreyi in animal models and levels of hemolysin expression in chancroidal lesions. In addition, the nature of the different susceptibilities of the target cells, possibly based on differences in (i) membrane composition, (ii) hemolysin receptor expression, or (iii) the ability of the affected cell to repair membrane damage induced by the hemolysin, will also be interesting subjects of future research.
Although our experiments measured target cell lysis, the H. ducreyi hemolysin may also have other, more subtle effects on cells. Lysis may occur only where there are many hemolysin-producing bacteria per target cell or where hemolysin expression is high. H. ducreyi grows as microcolonies in the rabbit model of
chancroid, suggesting that high bacterium-to-target-cell ratios can
occur in vivo (28) and that hemolysin-mediated lysis of
cells may occur in these areas of the lesion. In areas where there are
few bacteria per target cell or where hemolysin expression is low, the
hemolysin may alter cellular function rather than lyse the cell
outright. Effects of sublytic concentrations of hemolysin have been
documented with other bacteria, including the closely related S. marcescens hemolysin, which induces chemiluminescence in PMNs and
stimulates the release of leukotriene B4 (17).
Streptolysin O of Streptococcus pyogenes induces
interleukin-1
(IL-1
), IL-6, IL-8, and prostaglandin
E2 expression by keratinocytes (30), while the
E. coli hemolysin increases the release of leukotrienes from
PMNs and of IL-1
from monocytes and inhibits antigen
processing and presentation by murine macrophages
(46). Further exploration of the effects of sublytic doses
of hemolysin on cellular functions is needed to understand the
contribution of the H. ducreyi hemolysin to pathogenesis.
Our experiments showing that strains with cloned hemolysin genes were clearly more invasive than strains containing vector alone suggests a role for hemolysin in invasion of epithelial cells. Other organisms including Edwardsiella tarda, Shigella flexneri, and Listeria monocytogenes produce hemolysins that enhance invasion by allowing cell entry into or escape from the phagocytic vacuole (10, 14, 36). We saw no significant difference in invasion by the wild-type and isogenic hemolysin mutant strains, perhaps reflecting the difficulty in demonstrating small losses in invasiveness for an organism in which only ca. 1% of the inoculum is internalized. Alternatively, the effect of deleting only one of many factors required for invasiveness may be difficult to measure. Other researchers have demonstrated that mutants defective in lipooligosaccharide biosynthesis are impaired in invasion of HFEs; however, this may simply be a consequence of their decreased adherence to these cells (12). This is not the case for hemolysin, since wild-type, mutant, and overexpressing strains adhered at similar levels to HEp-2 cells. Experiments on the regulation of hemolysin expression, expression levels of hemolysin in vivo, and the mechanism of invasion of H. ducreyi are needed to clarify the role of hemolysin in invasion of this organism.
While several researchers have confirmed invasion of epithelial cells by H. ducreyi (12, 39), invasion of fibroblasts is more controversial. Lammel et al. reported that H. ducreyi could be found within HFFs by transmission electron microscopy (19). However, Alfa et al. were unable to confirm this observation and further demonstrated lack of invasion of HFFs by H. ducreyi in a gentamicin protection assay (1). The fact that HFFs are sensitive targets for hemolysin may suggest that H. ducreyi lyses these cells, confounding identification of intracellular bacteria by microscopy and allowing an influx of gentamicin that kills intracellular bacteria. This is apparently the case with wild-type P. mirabilis, which expresses a hemolysin that lyses human renal epithelial cells, resulting in an apparent decrease in invasion compared to hemolysin-deficient mutants in gentamicin protection assays (8).
The in vivo role of the hemolysin in chancroid pathogenesis is still unclear in human and animal models of chancroid. Palmer et al. evaluated a hemolysin-deficient mutant in a human model of H. ducreyi infection and found that the mutant produced erythema and pustules similar to the wild-type parent; they concluded that hemolysin plays a minor role in early lesion development (24). However, this model does not fully mimic chancroidal disease, since later stages of infection (ulceration, immune system avoidance, and transmission) cannot be evaluated and inoculations are made on the upper arm, not on genital skin. In contrast, a role for hemolysin in survival in its only known niche, the human host, is suggested by the observations that (i) all strains of H. ducreyi express hemolysin in vitro; (ii) hemolysin is produced in vivo, since both humans and animals produce antibodies to HhdA after infection with H. ducreyi (11); and (iii) the target cell range of hemolysin includes clinically relevant cell types. Further studies evaluating the levels of hemolysin expression in vivo, the sublytic effects of hemolysin on target cells, and the effect of hemolysin on different animal models of chancroid are needed to clarify the contribution of hemolysin to the pathogenesis of human disease.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by grant AI33522 from the National Institutes of Health to P.A.T. G.E.W. is supported by NIH STD/AIDS Research Training Grant T32 AI07140.
We thank Steve Moseley, Stephen Lory, Derek Wood, and Rodney Welch for helpful discussions and critical review of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Infectious Diseases, Box 359779, Harborview Medical Center, 325 Ninth Ave., Seattle, WA 98104. Phone: (206) 731-4926. Fax: (206) 731-8752. E-mail: patotten{at}u.washington.edu.
Editor: E. I. Tuomanen
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Alfa, M. J.,
P. DeGagne, and T. Hollyer.
1993.
Haemophilus ducreyi adheres to but does not invade cultured human foreskin cells.
Infect. Immun.
61:1735-1742 |
| 2. | Alfa, M. J., P. DeGagne, and P. A. Totten. 1996. Haemophilus ducreyi hemolysin acts as a contact cytotoxin and damages human foreskin fibroblasts in cell culture. Infect. Immun. 64:2349-2352[Abstract]. |
| 3. |
Blanton, R. A.,
T. S. Kupper,
J. K. McDougall, and S. Dower.
1989.
Regulation of interleukin 1 and its receptor in human keratinocytes.
Proc. Natl. Acad. Sci. USA
86:1273-1277 |
| 4. | Braun, V., R. Ondraczek, and S. Hobbie. 1993. Activation and secretion of Serratia hemolysin. Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. 278:306-315. |
| 5. |
Brentjens, R. J.,
M. Ketterer,
M. A. Apicella, and S. M. Spinola.
1996.
Fine tangled pili expressed by Haemophilus ducreyi are a novel class of pili.
J. Bacteriol.
178:808-816 |
| 6. | Cameron, D. W., J. N. Simonsen, L. J. D'Costa, A. R. Ronald, G. M. Maitha, M. N. Gakinya, M. Cheang, J. O. Nydinya-Achola, P. Piot, R. C. Brunham, and F. A. Plummer. 1989. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet ii:403-407. |
| 7. |
Campagnari, A. A.,
L. M. Wild,
G. E. Griffiths,
R. J. Karalus,
M. A. Wirth, and S. M. Spinola.
1991.
Role of lipooligosaccharides in experimental dermal lesions caused by Haemophilus ducreyi.
Infect. Immun.
59:2601-2608 |
| 8. |
Chippendale, G. R.,
J. W. Warren,
A. L. Trifillis, and H. L. T. Mobley.
1994.
Internalization of Proteus mirabilis by human renal epithelial cells.
Infect. Immun.
62:3115-3121 |
| 9. |
Cope, L. D.,
S. Lumbley,
J. L. Latimer,
J. Klesney-Tait,
M. K. Stevens,
L. S. Johnson,
M. Purven,
J. R. S. Munson,
T. Lagergard,
J. D. Radolf, and E. J. Hansen.
1997.
A diffusible cytotoxin of Haemophilus ducreyi.
Proc. Natl. Acad. Sci. USA
94:4056-4061 |
| 10. | Cossart, P. 1994. Listeria monocytogenes: strategies for entry and survival in cells and tissues, p. 285-304. In B. Tindall (ed.), Bailliere's clinical infectious diseases, vol. 1. Bailliere, Philadelphia, Pa. |
| 11. |
Dutro, S. M.,
G. E. Wood, and P. A. Totten.
1999.
Prevalence of, antibody response to, and protective immunity induced by Haemophilus ducreyi hemolysin.
Infect. Immun.
67:3317-3328 |
| 12. |
Gibson, B. W.,
A. A. Campagnari,
W. Melaugh,
N. J. Phillips,
M. A. Apicella,
S. Grass,
J. Wang,
K. L. Palmer, and J. R. S. Munson.
1997.
Characterization of a transposon Tn916-generated mutant of Haemophilus ducreyi 35000 defective in lipooligosaccharide biosynthesis.
J. Bacteriol.
179:5062-5071 |
| 13. | Hansen, E. J., J. L. Latimer, S. E. Thomas, M. Helminen, W. L. Albritton, and J. D. Radolf. 1992. Use of electroporation to construct isogenic mutants of Haemophilus ducreyi. J. Bacteriol. 16:5442-5449. |
| 14. | High, N., J. Mounier, M. Prevost, and P. Sansonetti. 1992. IpaB of Shigella flexneri causes entry into epithelial cells and escape from the phagocytic vacuole. EMBO J. 11:1991-1999[Medline]. |
| 15. | Hirono, I., N. Tange, and T. Aoki. 1997. Iron-regulated haemolysin gene from Edwardsiella tarda. Mol. Microbiol. 24:851-856[Medline]. |
| 16. | Hoiseth, S. K., and B. A. D. Stocker. 1981. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291:238-239[Medline]. |
| 17. |
Konig, W.,
Y. Faltin,
J. Scheffer,
H. Schoffler, and V. Braun.
1987.
Role of cell-bound hemolysin as a pathogenicity factor for Serratia infections.
Infect. Immun.
55:2554-2561 |
| 18. |
Korth, M. J.,
R. A. Schneider, and S. L. Mosely.
1991.
An F41-K88-related genetic determinant of bovine septicemic Escherichia coli mediates expression of CS31A fimbriae and adherence to epithelial cells.
Infect. Immun.
59:2333-2340 |
| 19. | Lammel, C. J., N. P. Dekker, J. Palefsky, and G. F. Brooks. 1993. In vitro model of Haemophilus ducreyi adherence to and entry into eukaryotic cells of genital origin. J. Infect. Dis. 167:642-650[Medline]. |
| 20. |
Morse, S. A.
1989.
Chancroid and Haemophilus ducreyi.
Clin. Microbiol. Rev.
2:137-157 |
| 21. | Palmer, K. L., W. E. Goldman, and J. R. S. Munson. 1996. An isogenic haemolysin-deficient mutant of Haemophilus ducreyi lacks the ability to produce cytopathic effects on human foreskin fibroblasts. Mol. Microbiol. 21:13-19[Medline]. |
| 22. |
Palmer, K. L.,
S. Grass, and J. R. S. Munson.
1994.
Identification of a hemolytic activity elaborated by Haemophilus ducreyi.
Infect. Immun.
62:3041-3042 |
| 23. | Palmer, K. L., and J. R. S. Munson. 1995. Cloning and characterization of the genes encoding the haemolysin of Haemophilus ducreyi. Mol. Microbiol. 18:821-830[Medline]. |
| 24. | Palmer, K. L., A. C. Thornton, K. R. Fortney, A. F. Hood, J. R. S. Munson, and S. M. Spinola. 1998. Evaluation of an isogenic hemolysin-deficient mutant in the human model of Haemophilus ducreyi infection. J. Infect. Dis. 178:191-199[Medline]. |
| 25. | Plummer, F. A., J. N. Simonsen, D. W. Cameron, J. O. Ndinya-Achola, J. K. Kreiss, M. N. Gakinya, P. Waiyaki, M. Cheang, P. Piot, A. R. Ronald, and E. N. Ngugi. 1991. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J. Infect. Dis. 163:233-239[Medline]. |
| 26. |
Poole, K., and V. Braun.
1988.
Iron regulation of Serratia marcescens hemolysin gene expression.
Infect. Immun.
56:2967-2971 |
| 27. |
Poole, K.,
E. Schiebel, and V. Braun.
1988.
Molecular characterization of the hemolysin determinant of Serratia marcescens.
J. Bacteriol.
170:3177-3188 |
| 28. | Purcell, B. K., J. A. Richardson, J. D. Radolf, and E. J. Hansen. 1991. A temperature-dependent rabbit model for production of dermal lesions by Haemophilus ducreyi. J. Infect. Dis. 164:359-367[Medline]. |
| 29. |
Purven, M., and T. Lagergard.
1992.
Haemophilus ducreyi, a cytotoxin-producing bacterium.
Infect. Immun.
60:1156-1162 |
| 30. | Ruiz, N., B. Want, A. Pentland, and M. Caparon. 1998. Streptolysin O and adherence synergistically modulate proinflammatory responses of keratinocytes to group A streptococci. Mol. Microbiol. 27:337-346[Medline]. |
| 31. | Sambrook, J., E. F. Frisch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 32. |
Schiebel, E.,
H. Schwarz, and V. Braun.
1989.
Subcellular location and unique secretion of the hemolysin of Serratia marcescens.
J. Biol. Chem.
264:16311-16320 |
| 33. | Schonherr, R., M. Hilger, S. Broer, R. Benz, and V. Braun. 1994. Interaction of Serratia marcescens hemolysin (ShlA) with artificial and erythrocyte membranes. Eur. J. Biochem. 223:655-663[Medline]. |
| 34. | Spinola, S. M., A. Orazi, J. N. Arno, K. Fortney, O. Kotylo, C. Chen, A. A. Campagnari, and A. F. Hood. 1996. Haemophilus ducreyi elicits a cutaneous infiltrate of CD4 cells during experimental human infection. J. Infect. Dis. 173:394-402[Medline]. |
| 35. | Spinola, S. M., L. M. Wild, M. A. Apicella, A. A. Gaspari, and A. A. Campagnari. 1994. Experimental human infection with Haemophilus ducreyi. J. Infect. Dis. 169:1146-1150[Medline]. |
| 36. | Strauss, E. J., N. Ghori, and S. Falkow. 1997. An Edwardsiella tarda strain containing a mutation in a gene with homology to shlB and hpmB is defective for entry into epithelial cells in culture. Infect. Immun. 65:3924-3932[Abstract]. |
| 37. | Strickberger, M. W. 1985. Genetics, 3rd ed. Macmillan Publishing Co., New York, N.Y. |
| 38. | Swihart, K. G., and R. A. Welch. 1991. Cytotoxic activity of the Proteus hemolysin HpmA. Infect. Immun. 58:1861-1869. |
| 39. |
Totten, P. A.,
J. C. Lara,
D. V. Norn, and W. E. Stamm.
1994.
Haemophilus ducreyi attaches to and invades cultured human foreskin epithelial cells in vitro.
Infect. Immun.
62:5632-5640 |
| 40. | Totten, P. A., W. R. Morton, G. H. Knitter, A. M. Clark, N. B. Kiviat, and W. E. Stamm. 1994. A primate model for chancroid. J. Infect. Dis. 169:1284-1290[Medline]. |
| 41. | Totten, P. A., D. V. Norn, and W. E. Stamm. 1995. Characterization of the hemolytic activity of Haemophilus ducreyi. Infect. Immun. 63:4409-4416[Abstract]. |
| 42. |
Totten, P. A., and W. E. Stamm.
1994.
Clear broth and plate media for culture of Haemophilus ducreyi.
J. Clin. Microbiol.
32:2019-2023 |
| 43. | Trees, D. L., and S. A. Morse. 1995. Chancroid and Haemophilus ducreyi: an update. Clin. Microbiol. Rev. 8:357-375[Abstract]. |
| 44. |
Uphoff, T. S., and R. A. Welch.
1990.
Nucleotide sequencing of the Proteus mirabilis calcium-independent hemolysin genes (hpmA and hpmB) reveals sequence similarity to the Serratia marcescens hemolysin genes (shlA and shlB).
J. Bacteriol.
172:1206-1216 |
| 45. | Wasserheit, J. N. 1992. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex. Transm. Dis. 19:61-77[Medline]. |
| 46. | Welch, R. A. 1991. Pore-forming cytolysins of Gram-negative bacteria. Mol. Microbiol. 5:521-528[Medline]. |
| 47. | Welch, R. A., C. Forestier, A. Lobo, S. Pellett, J. W. Thomas, and G. Rowe. 1992. The synthesis and function of the Escherichia coli hemolysin and related RTX exotoxins. FEMS Microbiol. Immunol. 105:29-36. |
| 48. |
Willson, P. J.,
W. L. Albritton,
L. Slaney, and J. K. Setlow.
1989.
Characterization of a multiple antibiotic resistance plasmid from Haemophilus ducreyi.
Antimicrob. Agents Chemother.
33:1627-1630 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»